47 results about "Keratoconjunctivitis" patented technology

The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and / or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.

The invention provides apparatuses and methods for detecting ocular surface defects. The methods and / or an apparatus of the invention can be used to detect ocular surface diseases, such as dry eye, uveitis, conjunctivitis, keratitis, keratoconjunctivitis, vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), autoimmune disorders of the ocular surface, meibomianitis, conjunctival hyperemia, eyelid hyperemia, ocular rosacea, ocular inflammation, or eye lid swelling.

The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.

An ophthalmic composition is provided which is capable of enhancing a barrier function of a lipid layer that constitutes a tear film, for thereby restricting and curing corneal disorders such as dry eye. It is also an object of the invention to provide the ophthalmic composition with anti-inflammatory and antimicrobial effects for thereby advantageously preventing and easing corneal / conjunctival disorders such as keratoconjunctivitis. In the present invention, apolipoprotein A-1 is included, as an active ingredient, in the ophthalmic composition.

Embodiments of the invention relate to single nucleotide polymorphisms (SNPs) in Thrombospondin 1 gene (THB-S1) that are herein linked to an increased risk for dry eye (also known as keratoconjunctivitis). The polymorphisms disclosed herein are directly useful for the diagnosis of an increased risk for dry eye, as well as for the determination of patient treatment pre- and post-surgery (e.g. pre and post refractive eye surgery) or in a patient having a condition associate with dry eye (e.g. diabetes, lupus, scleroderma, Sjogren's syndrome, thyroid disorders, vitamin A deficiency, and rheumatoid arthritis). Computer systems and medium are also enclosed. The SNPs can be present in unique combinations, or as specific haplotypes indicative of dry eye. The SNPs linked to an increased risk for dry eye include rs1478604, rs2228261, and rs2292305.

A topical ophthalmic composition comprising 17-β-estradiol or its derivatives and an androgen in pharmaceutically acceptable vehicle, and method of using same for the alleviation of kerato-conjunctivitis sicca KCS (dry eye syndrome DES).

The invention relates to a novel mixed type cornea and conjuctiva intravital staining agent. A staining agent comprises a mixed solution of a fluorescein sodium aqueous solution and a lissamine green aqueous solution. The mixed type cornea and conjuctiva intravital staining agent has the advantages that the staining agent can stain cornea and bulbar conjunctiva, stains at one time, has small stimulus to eye tissues and is easily accepted by patients; the staining agent is mainly used for early diagnosing and evaluating dry eye syndrome, keratohelcosis, keratoconjunctivitis (KCS), arborization corneal epithelium herpes, Sjogren syndrome and the like.

The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and / or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and / or conjunctiva, and / or to the Meibomian gland.

The present invention provides a composition comprising two or more of the following pharmaceutically active compounds: (i) an alpha 2 adrenergic agonist; (ii) a corticosteroid; (iii) a lymphocyte function-associated antigen antagonist; (iv) a non-steroidal anti-inflammatory drug (NSAID); (v) a sodium channel blocker; and (vi) an antibiotic, provided at least one of the pharmaceutically active compound is selected from the group consisting of (i) alpha 2 adrenergic agonist and (ii) corticosteroid. The present invention also provides a method for using such composition to treat an eye disorder such as a dry eye syndrome; ocular graft-versus-host-disease; ocular rosacea; allergic conjunctivitis; autoimmune ocular surface disease; thygeson's superficial punctuate keratopathy; herpes zoster keratitis; Stevens-Johnson syndrome; keratitis; conjunctivitis; blepharitis; blepharochalasis; conjunctivochalasis; blepharoconjunctivitis; blepharokeratoconjunctivitis; post-operative inflammation or pain from ocular surgery; scleritis; episcleritis; anterior uveitis; iritis; cyclitis; ocular surface vascular disorder; ulcerative keratitis; photokeratitis; dacryocystitis; eyelid disorder; congenital alacrima; xerophthalmia; dacryoadenitis; vernal keratoconjunctivitis; pinguecula; and / or ocular surface disorder induced by chemical burns, thermal burns, or physical insult to the ocular surface.

Adenoviral infections and in particular ocular adenoviral infections, e.g. keratoconjunctivitis, can be treated or alleviated by the administration of a substance, interfering with the interaction between the virus and the sialic acid receptor, in a therapeutically effective amount.

The invention discloses a preparation method of a Tibetan drug (Jiumei Mingliang) for treating keratoconjunctivitis. The Jiumei Mingliang comprises an active component or an active ingredient and a pharmaceutically acceptable excipient, wherein the active component is prepared by Berberis extract, saffron, and bear bile powder according to a certain weight proportion. The Jiumei Mingliang can be prepared into ophthalmic preparations such as eye drip and eye ointment. The Jiumei Mingliang can clear away the heat evil, reduce the pathogenic fire, and remove the nebula to improve visual acuity. In the traditional Tibetan medicine, the Tibetan drug can treat the eye diseases induced by 'wind' and 'bile' disorder. In the traditional Chinese medicine, the Tibetan drug can treat the diseases induced by flaming-up of the liver fire and collateral impairment by noxious heat: hyperemia of bulbar conjunctiva, much epiphora, photophobia and lacrimation, conjunctivitis and keratitis.

The invention relates to a Chinese medicinal composition for treating vernal keratoconjunctivitis. The Chinese medicinal composition is prepared from the following components of carissa macrocarpa, all-grass of climbing violet, root of Chinese hibiscus, radix clematidis, pepperweed seed, groundsel, pagoda tree fruit, horsetail, cuscuta chinensis, semen plantaginis and borneol. The Chinese medicinal composition for treating the vernal keratoconjunctivitis, disclosed by the invention, can be clinically applied to treating the keratoconjunctivitis.

The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.

The invention relates to an application of cydiodine to treatment of keratoconjunctivitis and particularly relates to a solid pharmaceutical composition used to be dropped into eyes. The solid pharmaceutical composition comprises cydiodine and a diluent. The invention also provides a medicine box product comprising a packaging box, the solid pharmaceutical composition packaged in the packaging box and a solvent for dissolving the solid pharmaceutical composition. The solid pharmaceutical composition provided by the invention can be used for preventing and treating inflammatory diseases of eyes, such as bacterial or viral inflammatory diseases on parts such as conjunctiva, cornea and the like.

Chinese medicine for treating keratoconjunctivitis is prepared by Michdia yunnanensis Franch, elaeagnus umbellate, clematis leaves, paniculate swallowwort roots, honeysuckles, Chinese Sericocalyx herbs, sonerila laeta stapf, climbing groundsel herbs, cicada sloughs and cocklebur fruits. The Chinese medicine can be clinically applied to treating the keratoconjunctivitis.

The invention discloses a traditional Chinese medicine composition for treating keratoconjunctivitis, which is prepared from Chinese violet, cassia seed, diffusa, selfheal, root of Hibiscus rosa-sinensis, radix clematidis, sophora fruit, horsetail, golden cypress, semen plantaginis and borneol. Clinically, the Traditional Chinese medicine composition can be used for treating keratoconjunctivitis.

The present disclosure provides methods for the treatment of an allergic ocular disease (e.g., allergic conjunctivitis, keratoconjunctivitis, or giant papillary conjunctivitis). In particular, the present disclosure provides methods for the treatment of an allergic ocular disease through administration of antibodies that bind to human Siglec-8 or compositions comprising said antibodies. The present disclosure also provides articles of manufacture or kits comprising antibodies that bind to human Siglec-8 for the treatment of an allergic ocular disease.

The invention discloses a traditional Chinese medicine preparation for treating wind-evil attack type keratoconjunctivitis. The traditional Chinese medicine preparation is prepared from the following components: Chinese brake herb, tuber fleeceflower stem, palmleaf raspberry fruit, valerian root, manchurian wildginger, borneol and snake slough. The traditional Chinese medicine preparation disclosed by the invention can be clinically used for treating wind-evil attack type keratoconjunctivitis.

Compositions for modulating an inflammation comprise a fluoroquinolone having one of Formulae I-VIII. Methods for modulating an inflammation comprise administering such compositions to a subject in need thereof. The compositions and methods are suitable for modulating an ocular or ophthalmic inflammation, including uveitis, vernal keratoconjunctivitis, or inflammation associated with contact lens-associated corneal infiltrates.

The invention provides a traditional Chinese medicine composition for treating keratoconjunctivitis due to congestion and excess of dampness-heat. The traditional Chinese medicine composition is prepared from serissa serissoides, drymaria diandra, hemigraphis procumbens (Lour.) Merr., coptis root, Chinese taxillus herb, capsella bursa-pastoris, scorzonera subacaulis, paniculate swallowwort root and cape jasmine fruit. The traditional Chinese medicine composition can be clinically used for treating keratoconjunctivitis due to congestion and excess of dampness-heat.

The present invention relates to a combination comprising HSV-1 and HSV-2 binding monoclonal antibodies or fragments thereof and antiviral agents, the pharmaceutical formulations comprising said combination, optionally together with an excipient pharmaceutically acceptable and its use in the prophylaxis and / or treatment of herpes virus infections, including genital herpes, HSV gingivostomatitis and recurrent herpes labialis, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in the immunocompromised host and HSV keratitis keratoconjunctivitis.

Embodiments of the invention involve treating ophthalmology conditions by the topical or oral use of acetylcholinesterase inhibitors. By effectively reducing or eliminating the population of Demodex mites in affected areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the ophthalmological afflictions than any previously described method. Embodiments of the invention are useful for treating ocular afflictions caused by Demodex-induced inflammatory eye conditions, including meibomian gland dysfunction, conjunctivitis, keratoconjunctivitis, hyperemia, blepharitis and dry eye disease.

[PROBLEMS TO BE SOLVED]To provide a method of advantageously improving a transdermal permeation amount of a steroid drug to diseased portions when treating ophthalmic diseases such as chalazion, blepharitis, allergic conjunctivitis, vernal keratoconjunctivitis, and meibomian gland dysfunction.[SOLUTION]To provide the transdermal drug delivery system for administering a drug via the eyelid skins that have been treated with a microneedle array, featured in that the drug is a water-soluble steroid, and the transdermal drug delivery system is a water-containing base adhesive skin patch.

The present invention relates to an ocular surface applied medicament for treating drug used for treating eyes immunological disease and inhibiting proliferation and neovascularization, wherein rapamycin is used as active component at 0.01-2% by weight. And the ocular surface applied medicament provided by the present invention can be used for treating syndrome, allergic conjunctivitis, giant papillary conjunctivitis, vernal conjunctivitis, atopic keratoconjunctivitis, pterygium, Mooren ulcer, Stevens Johnson syndrome, dry eye, scleritis, episcleritis, various tunicauveae inflammation and the like, and also can be used for treating eye trauma after cornea transplanting and preventing fibrogenesis, adhesion, and cicatrisation, and inhibiting neovascularization after operation.

The invention discloses a Tibetan drug for treating keratoconjunctivitis. The Tibetan drug is prepared from an active ingredient or the active ingredient and pharmaceutically acceptable auxiliary materials, wherein the active ingredient is prepared from sal ammoniac, travertine, goethite, caraway, little multibanded krait, liliaceae, safflower carthamus, sweet iris flower, common heronsbill herb and berberis dictyophylla according to a certain weight ratio. The Tibetan drug can be prepared into any one common dosage form for oral administration, has the effects of clearing heat to reduce fire and removing nebula for improving eyesight, and is used for treating itching pain due to hot eyes, lachrymation, trachoma and keratoconjunctivitis.

The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.